317357-19-0

Basic information

• Product Name: 1-Pyrrolidinecarboxylic acid, 2-(hydroxymethyl)-4-phenoxy-, 1,1-dimethylethyl ester, (2S,4S)-
• CAS NO: 317357-19-0
• Molecular Formula: C16H23NO4
• Molecular Weight: 293.363
• Mol File: 317357-19-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-Pyrrolidinecarboxylic acid, 2-(hydroxymethyl)-4-phenoxy-, 1,1-dimethylethyl ester, (2S,4S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxylic acid, 2-(hydroxymethyl)-4-phenoxy-, 1,1-dimethylethyl ester, (2S,4S)-(317357-19-0)
• EPA Substance Registry System: 1-Pyrrolidinecarboxylic acid, 2-(hydroxymethyl)-4-phenoxy-, 1,1-dimethylethyl ester, (2S,4S)-(317357-19-0)

Safety Data

• Hazardous Substances Data: 317357-19-0(Hazardous Substances Data)

Upstream product

• 93967-75-0 methyl (1-tert-butoxycarbonyl)-(4S)-phenoxy-(2S)-pyrrolidinylcarboxylate 
• 108-95-2 phenol 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 147266-79-3 (2S,4S)-1-(tert-butoxycarbonyl)-4-phenoxypyrrolidine-2-carboxylic acid 

Downstream Products

• 874773-08-7 (4S)-phenoxy-(2S)-phenoxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1266099-67-5 (2S,4S)-allyl 2-(hydroxymethyl)-4-phenoxypyrrolidine-1-carboxylate 
• 317357-20-3 (2S,4S)-1-tert-butoxycarbonyl-4-phenoxy-2-pyrrolidine carbaldehyde 

Relevant articles and documents

SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF

Disclosed are a class of SMAC mimetics used as IAP inhibitors, and in particular disclosed are compounds as shown in formula (I), isomers thereof, and pharmaceutically acceptable salts thereof. The IAP inhibitors are drugs for treating cancers, in particu

TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE

The present invention provides compounds of Formula (I): wherein A and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

VLA-4 INHIBITORS

The present invention relates to a compound represented by the following formula (I): (wherein, W represents WA-A1 -WB - (in which, WA is substituted or unsubstituted aryl, etc., A1 is -NR1-, single bond, -C(O)-, etc., and WB is substituted or unsubstituted arylene, etc.), R is single bond, -NH-, -OCH2-, alkenylene, etc., X is -C(O) -CH2-, etc., and M is, for example, the following formula: (in which, R11, R12 and R13 each independently represents hydrogen, hydroxyl, amino, halogen, etc., R14 is hydrogen or lower alkyl, Y represents -CH2-O-, etc., Z is substituted or unsubstituted arylene, etc., A2 is single bond, etc, and R10 is hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same. This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VAL-4 and exhibits high bioavailability so that it is useful as a preventive and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.